Forman S J, Krance R A, O'Donnell M R, Nademanee A P, Snyder D S, Fahey J L, Schmidt G M, Zaia J A, Lipsett J A, Findley D O
Transplantation. 1987 May;43(5):650-3. doi: 10.1097/00007890-198705000-00009.
Sixty-nine patients with acute nonlymphocytic leukemia in first remission received total-body irradiation and chemotherapy followed by allogeneic bone marrow transplantation from histocompatible sibling donors. Patient age was between 1 and 41 years: 20 patients 1-19 years (group 1); 27 patients 20-29 years (group 2); and 22 patients 30-41 years (group 3). Two pretransplant radiochemotherapy regimens were employed: The first 45 patients received total-body irradiation (in a single dose) with cytosine arabinoside and cyclophosphamide; the next 24 patients received total-body irradiation (in a fractionated schedule) with cyclophosphamide alone. For all patients, actuarial disease-free survival is 51% (37 of 69 patients are alive and in continuous remission between 5 months and 9.3 years, median 3.7 years). For group 1 actuarial survival is 56%, group 2 48%, and group 3 48%. When analyzed for pretransplant factors that might predict disease-free survival after bone marrow transplantation neither patient age, white cell count at the time of diagnosis, FAB leukemic subtype, length of time before achieving remission, nor length of time between remission and bone marrow transplantation were established as prognostic.
69例首次缓解的急性非淋巴细胞白血病患者接受了全身照射和化疗，随后接受了来自组织相容性同胞供者的异基因骨髓移植。患者年龄在1至41岁之间：20例患者年龄为1 - 19岁（第1组）；27例患者年龄为20 - 29岁（第2组）；22例患者年龄为30 - 41岁（第3组）。采用了两种移植前放化疗方案：前45例患者接受全身照射（单次剂量）联合阿糖胞苷和环磷酰胺；接下来的24例患者接受全身照射（分次方案）联合单独使用环磷酰胺。对所有患者而言，无病生存率为51%（69例患者中有37例存活且处于持续缓解状态，缓解时间为5个月至9.3年，中位时间为3.7年）。第1组的无病生存率为56%，第2组为48%，第3组为48%。在分析可能预测骨髓移植后无病生存的移植前因素时，患者年龄、诊断时的白细胞计数、FAB白血病亚型、达到缓解前的时间长度以及缓解与骨髓移植之间的时间长度均未被确立为预后因素。
